| P50 | author | James P Nataro | Q61771354 |
| P2093 | author name string | Eileen M Barry | |
| | Mauricio J Farfán | |
| | Cecilia S Toro | |
| P2860 | cites work | Aggregative adherence fimbriae contribute to the inflammatory response of epithelial cells infected with enteroaggregative Escherichia coli. | Q54638065 |
| | Invasive Shigella flexneri activates NF-kappa B through a lipopolysaccharide-dependent innate intracellular response and leads to IL-8 expression in epithelial cells | Q73948765 |
| | Shigella chromosomal IpaH proteins are secreted via the type III secretion system and act as effectors | Q79532962 |
| | Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media | Q81445405 |
| | A secreted anti-activator, OspD1, and its chaperone, Spa15, are involved in the control of transcription by the type III secretion apparatus activity in Shigella flexneri | Q81785474 |
| | Shigella flexneri type III secretion system effectors OspB and OspF target the nucleus to downregulate the host inflammatory response via interactions with retinoblastoma protein | Q24315859 |
| | One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products | Q27860842 |
| | A functional genomic yeast screen to identify pathogenic bacterial proteins | Q33315560 |
| | Global burden of Shigella infections: implications for vaccine development and implementation of control strategies | Q33749510 |
| | Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans | Q34003433 |
| | The Shigella flexneri effector OspG interferes with innate immune responses by targeting ubiquitin-conjugating enzymes | Q34048081 |
| | Shigella enterotoxin 1: an enterotoxin of Shigella flexneri 2a active in rabbit small intestine in vivo and in vitro | Q34224319 |
| | MxiE regulates intracellular expression of factors secreted by the Shigella flexneri 2a type III secretion system | Q34316975 |
| | Analysis of virulence and inflammatory potential of Shigella flexneri purine biosynthesis mutants | Q34941041 |
| | OspF and OspC1 are Shigella flexneri type III secretion system effectors that are required for postinvasion aspects of virulence | Q35073836 |
| | Identification and cloning of a novel plasmid-encoded enterotoxin of enteroinvasive Escherichia coli and Shigella strains | Q35455031 |
| | Engineered deltaguaB-A deltavirG Shigella flexneri 2a strain CVD 1205: construction, safety, immunogenicity, and potential efficacy as a mucosal vaccine | Q35510455 |
| | The bacterial injection kit: type III secretion systems | Q36194906 |
| | Shigella spp. and enteroinvasive Escherichia coli pathogenicity factors | Q36267084 |
| | Molecular pathogenesis of Shigella spp.: controlling host cell signaling, invasion, and death by type III secretion. | Q36422508 |
| | Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road | Q36844719 |
| | Identification of the secretion and translocation domain of the enteropathogenic and enterohemorrhagic Escherichia coli effector Cif, using TEM-1 beta-lactamase as a new fluorescence-based reporter | Q37008377 |
| | Plaque formation by virulent Shigella flexneri | Q37048229 |
| | Vaccination against shigellosis: is it the path that is difficult or is it the difficult that is the path? | Q37232206 |
| | Shigella type III secretion effectors: how, where, when, for what purposes? | Q37373930 |
| | Pathogenesis of shigella diarrhea: evidence for an N-linked glycoprotein shigella toxin receptor and receptor modulation by beta-galactosidase | Q38351384 |
| | Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208. | Q39146446 |
| | Prevalence of Shigella enterotoxins 1 and 2 among Shigella strains isolated from patients with traveler's diarrhea | Q39453145 |
| | Secretion of Ipa proteins by Shigella flexneri: inducer molecules and kinetics of activation. | Q39831093 |
| | An injected bacterial effector targets chromatin access for transcription factor NF-kappaB to alter transcription of host genes involved in immune responses | Q40198172 |
| | The secretion of the Shigella flexneri Ipa invasins is activated by epithelial cells and controlled by IpaB and IpaD. | Q40793797 |
| | Contact of Shigella with host cells triggers release of Ipa invasins and is an essential function of invasiveness | Q40806867 |
| | Developing live Shigella vaccines using lambda Red recombineering | Q41452880 |
| | The virulence plasmid pWR100 and the repertoire of proteins secreted by the type III secretion apparatus of Shigella flexneri | Q42638971 |
| | Shigella effector IpaH9.8 binds to a splicing factor U2AF(35) to modulate host immune responses | Q44053369 |
| | IL-8 is a key chemokine regulating neutrophil recruitment in a new mouse model of Shigella-induced colitis. | Q51189374 |
| | Regulation of transcription by the activity of the Shigella flexneri type III secretion apparatus. | Q54546861 |
| P433 | issue | 3 | |
| P304 | page(s) | 332-339 | |
| P577 | publication date | 2011-02-02 | |
| P1433 | published in | FEMS Immunology and Medical Microbiology | Q15767550 |
| P1476 | title | Shigella enterotoxin-2 is a type III effector that participates in Shigella-induced interleukin 8 secretion by epithelial cells | |
| P478 | volume | 61 | |